Business Update

Merck's cervical cancer vaccine Gardasil added to U.S. CDC Vaccines for Children contract

Published in Vaccine Weekly, November 29th, 2006

Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention (CDC) has added Merck's cervical cancer vaccine, Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant Vaccine) to the U.S. Centers for Disease Control's (CDC) Vaccines for Children (VFC) contract for girls and women aged 9 to 18.

Gardasil was approved on June 8 by the U.S. Food and Drug Administration (FDA) for use in girls and women ages 9 to 26 years. Gardasil is the first vaccine available for the prevention of HPV types 16- and 18-related cervical cancer, cervical pre-cancers (CIN 2/3 and AIS), vulvar pre-cancers (VIN 2/3) and vaginal pre-cancers (VaIN 2/3)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry